CHENGDU, China, January 6, 2015 /PRNewswire/ — Tianyin Pharmaceutical Co., Inc. (NYSE MKT: TPI), a pharmaceutical company that specializes in patented biopharmaceutical, modernized traditional Chinese medicine (mTCM), branded generics and active pharmaceutical ingredients (API) announces that Buchang Pharmaceutical’s management visited TPI’s Qionglai Facility (QLF) and met with Tianyin’s CEO. Buchang Pharmaceutical is one of the most distinguished enterprises in mTCM pharmaceutical manufacturing and distribution with a strong cardiovascular focus.
About Buchang Pharmaceutical
Buchang Pharmaceuticals ("Buchang"), headquartered at Xi’an, established in 1993, by Dr. Buchang Zhao, is a modern and hi-tech non-public enterprise focusing on research, production and distribution of medicines, health care and education in China. After 22 years development, the Company now has ten pharmaceutical manufacturing facilities, ten business departments, two hospitals and one college. Since inception, Buchang has been dedicated to science and technology and insisted on the principal of innovation. The main products, Buchang Naoxintong capsule, has won the golden medal on the 42nd World Invention Exhibition in Brussels of Belgium and the first brand to customers in China’s domestic medicine market and Wenxin Granule is a sole product of Chinese herb medicine to treat coronary heart disease and arrhythmia. Buchang exports internationally to Indonesia, Hong Kong, Malaysia, Thailand, Russia, Vietnam etc.
With 10 departments and more than 10,000 professional sales representatives covering 15,000 hospitals and 130,000 drug stores, Buchang has established a complete market network in China. The annual sales of Buchang were RMB 3.6 billion (approximately $510 million) in 2008, 5.2 billion (approximately $560 million) in 2009 and to 6.5 billion (approximately $1 billion) in 2010 with double digit growth annually.
For the value Buchang created to the state in the past years and outstanding contribution Buchang serviced to the public, Professor Buchang Zhao, and the president of Buchang Pharmaceuticals, Dr. Chao Zhao, were selected as members of NPC for consecutive years and received by state central leaders. For detailed information of Buchang Pharmaceutical in English version, please click: http://www.buchang.com/english/about.asp or http://www.buchang.com/ in Chinese version.
Headquartered in Chengdu, China, with Jiang, Guoqing as Company’s Chairman and CEO, TPI is a pharmaceutical company that specializes in the development, manufacturing, marketing and sales of patented biopharmaceutical, mTCM, branded generics and API. TPI currently manufactures a comprehensive portfolio of 58 products, 24 of which are listed in the highly selective national medicine reimbursement list, 10 are included in the essential drug list of China. For more information about TPI, please visit: http://www.tianyinpharma.com.
Safe Harbor Statement
The Statements which are not historical facts contained in this press release are forward-looking statements that involve certain risks and uncertainties including but not limited to risks associated with the uncertainty of future financial results, additional financing requirements, development of new products, government approval processes, the impact of competitive products or pricing, technological changes, the effect of economic conditions and other uncertainties detailed in the Company’s filings with the Securities and Exchange Commission.
For more information, please visit: http://www.tianyinpharma.com.
Tel: +86-28-8551-6696 (Chengdu, China)
23rd Floor, Unionsun Yangkuo Plaza
No. 2, Block 3, South Renmin Road
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/buchang-pharmaceutical-visits-tianyin-qionglai-facility-300016317.html